Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Recommendations for Diagnosis, Treatment and Care

[1]  M. Miravitlles,et al.  Validation of clinical control in COPD as a new tool for optimizing treatment , 2018, International journal of chronic obstructive pulmonary disease.

[2]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[3]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[4]  B. Celli.  Dissecting COPD exacerbations: time to rethink our definition , 2017, European Respiratory Journal.

[5]  Pere Almagro,et al.  Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable , 2017 .

[6]  Bartolomé R. Celli,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. , 2017, Archivos de bronconeumologia.

[7]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[8]  M. Postma,et al.  Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations , 2016, PharmacoEconomics.

[9]  K. Kostikas,et al.  Prediction and prevention of exacerbations and mortality in patients with COPD , 2016, Expert review of respiratory medicine.

[10]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[11]  K. Saverno,et al.  COPD exacerbation frequency and its association with health care resource utilization and costs , 2015, International journal of chronic obstructive pulmonary disease.

[12]  J. Roca,et al.  Effectiveness of community-based integrated care in frail COPD patients: a randomised controlled trial , 2015, npj Primary Care Respiratory Medicine.

[13]  N. Chavannes,et al.  Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial , 2014, BMJ : British Medical Journal.

[14]  N. Chavannes,et al.  Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[15]  P. Gibson,et al.  Sputum Inflammatory Cell-Based Classification of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease , 2013, PloS one.

[16]  Thierry Troosters,et al.  Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality , 2012, PloS one.

[17]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[18]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[19]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. , 2012, Archivos de bronconeumologia.

[20]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.

[21]  Josep Roca,et al.  Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.

[22]  Juan José Soler-Cataluña,et al.  Impacto multidimensional de las exacerbaciones de la EPOC , 2010 .

[23]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[24]  R. Rodríguez-Roisín,et al.  Frequent Chronic Obstructive Pulmonary Disease Exacerbators: How Much Real, How Much Fictitious? , 2010, COPD.

[25]  J. Soriano,et al.  Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007 , 2009, European Respiratory Journal.

[26]  J. Soriano,et al.  Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.

[27]  P. Shekelle,et al.  Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians , 2007, Annals of Internal Medicine.

[28]  E. Wouters,et al.  Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. , 2007, Respiratory medicine.

[29]  M. Decramer,et al.  Integrated care prevents hospitalisations for exacerbations in COPD patients , 2006, European Respiratory Journal.

[30]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[31]  M. Martínez-García,et al.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.

[32]  M. R. Rutten-van Mölken,et al.  Resource use and risk factors in high-cost exacerbations of COPD. , 2004, Respiratory medicine.

[33]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[34]  M. Martínez,et al.  Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. , 2004, Respiratory medicine.

[35]  J. Wedzicha,et al.  Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[36]  M. Perpiñá,et al.  Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario , 2001 .

[37]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.